Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ) Latest Company News

Oct 26, 2026, 07:58 UTC
Yisheng Pharmaceutical reported revenue of 435 million yuan, net profit of 21.24 million yuan and adjusted net profit of 11.7433 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 07:58 UTC
Yisheng Pharmaceutical reported third-quarter 2026 revenue of 96.8487 million yuan, down 34.72% year over year, and a net loss of 5.5911 million yuan, compared with a profit a year earlier; adjusted net profit was 4.8531 million yuan, up 26.24%.
Source:
- finance.sina.cn
Sep 21, 2026, 10:33 UTC
Jilin Provincial Medical Products Administration lifted risk-control measures on Yisheng Pharmaceutical after an on-site inspection confirmed safety hazards were eliminated, allowing the relevant production lines to resume operations in an orderly manner.
Source:
- finance.sina.cn
Aug 24, 2026, 13:09 UTC
Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.
Source:
- finance.sina.cn
Jul 7, 2026, 09:12 UTC
Yisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.
Source:
- finance.sina.cn
Jul 5, 2026, 08:33 UTC
Yisheng Pharmaceutical received a notice from Jilin Provincial Drug Administration on July 1, 2026, ordering the suspension of production and sales of Shengmai Injection and Bujin Tablets due to serious defects and safety hazards found during an inspection from June 26 to 28, 2026.
Source:
- finance.sina.cn
- finance.sina.cn

002566.SZ

Yisheng Pharmaceutical reported revenue of 435 million yuan, net profit of 21.24 million yuan and adjusted net profit of 11.7433 million yuan for the first three quarters of 2026.

Yisheng Pharmaceutical reported third-quarter 2026 revenue of 96.8487 million yuan, down 34.72% year over year, and a net loss of 5.5911 million yuan, compared with a profit a year earlier; adjusted net profit was 4.8531 million yuan, up 26.24%.

Jilin Provincial Medical Products Administration lifted risk-control measures on Yisheng Pharmaceutical after an on-site inspection confirmed safety hazards were eliminated, allowing the relevant production lines to resume operations in an orderly manner.

Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.

Yisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.

Yisheng Pharmaceutical received a notice from Jilin Provincial Drug Administration on July 1, 2026, ordering the suspension of production and sales of Shengmai Injection and Bujin Tablets due to serious defects and safety hazards found during an inspection from June 26 to 28, 2026.